Advances in the assessment and control of the effector functions of therapeutic antibodies
Authors:
Top Cited Papers
- 1 February 2011
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 10 (2) , 101-111
Abstract
The Fc (crystallizable fragment) region of therapeutic antibodies can have an important role in their safety and efficacy. Although much is known about the structure-activity relationship of antibodies and the factors that influence Fc effector functions, a process has not yet been defined to clearly delineate how Fc functionality should be assessed and controlled during antibody development and manufacturing. In this article, we summarize the current knowledge of antibody Fc functionality, provide a strategy for assessing the effector functions of different classes of therapeutic antibodies (including Fc fusion proteins) and propose a path for routine testing and controls for manufacturers of antibody products.Keywords
This publication has 63 references indexed in Scilit:
- Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor BindingMolecular & Cellular Proteomics, 2010
- Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteinsNature Biotechnology, 2010
- CYP-Mediated Therapeutic Protein-Drug InteractionsClinical Pharmacokinetics, 2010
- Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemiaHaematologica, 2009
- Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieuBlood, 2008
- Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG FcScience, 2008
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseNew England Journal of Medicine, 2008
- Utilization of Complement-Dependent Cytotoxicity To Measure Low Levels of Antibodies: Application to Nonstructural Protein 1 in a Model of Japanese Encephalitis VirusClinical and Vaccine Immunology, 2008
- Agalactosylated IgG antibodies depend on cellular Fc receptors forin vivoactivityProceedings of the National Academy of Sciences, 2007